KR20140107540A - 메틸날트렉손의 경구 조성물을 사용하는 오피오이드 유발성 변비의 치료 및 예방 방법 - Google Patents

메틸날트렉손의 경구 조성물을 사용하는 오피오이드 유발성 변비의 치료 및 예방 방법 Download PDF

Info

Publication number
KR20140107540A
KR20140107540A KR1020147020310A KR20147020310A KR20140107540A KR 20140107540 A KR20140107540 A KR 20140107540A KR 1020147020310 A KR1020147020310 A KR 1020147020310A KR 20147020310 A KR20147020310 A KR 20147020310A KR 20140107540 A KR20140107540 A KR 20140107540A
Authority
KR
South Korea
Prior art keywords
subject
mntx
pharmaceutical composition
methylnaltrexone
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147020310A
Other languages
English (en)
Korean (ko)
Inventor
에녹 볼티
Original Assignee
샐릭스 파마슈티컬스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 샐릭스 파마슈티컬스 리미티드 filed Critical 샐릭스 파마슈티컬스 리미티드
Publication of KR20140107540A publication Critical patent/KR20140107540A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020147020310A 2011-12-19 2012-12-19 메틸날트렉손의 경구 조성물을 사용하는 오피오이드 유발성 변비의 치료 및 예방 방법 Ceased KR20140107540A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161577654P 2011-12-19 2011-12-19
US61/577,654 2011-12-19
PCT/US2012/070612 WO2013096444A1 (en) 2011-12-19 2012-12-19 Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone

Publications (1)

Publication Number Publication Date
KR20140107540A true KR20140107540A (ko) 2014-09-04

Family

ID=48669445

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147020310A Ceased KR20140107540A (ko) 2011-12-19 2012-12-19 메틸날트렉손의 경구 조성물을 사용하는 오피오이드 유발성 변비의 치료 및 예방 방법

Country Status (11)

Country Link
US (2) US20130317050A1 (enExample)
EP (1) EP2793888A4 (enExample)
JP (2) JP2015501849A (enExample)
KR (1) KR20140107540A (enExample)
CN (2) CN110384701A (enExample)
AU (3) AU2012359013A1 (enExample)
BR (1) BR112014014805A2 (enExample)
CA (1) CA2859203C (enExample)
IL (1) IL233266A0 (enExample)
MX (1) MX2014007312A (enExample)
WO (1) WO2013096444A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2015191686A1 (en) * 2014-06-10 2015-12-17 Salix Pharmaceuticals, Inc. Methods of administering methylnaltrexone
EP3206491B1 (en) * 2014-10-17 2019-11-27 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
JP2019513355A (ja) * 2016-03-29 2019-05-30 コロナリーコンセプツ エルエルシー 便秘症を処置するための製剤
WO2023031955A1 (en) * 2021-08-28 2023-03-09 Redasani Vijayendrakumar Virendrakumar Ji Oral pharmaceutical compositions of methylnaltrexone and salt thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS601128A (ja) * 1983-06-15 1985-01-07 Shionogi & Co Ltd 作用持続型セフアクロル製剤
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
WO2003086415A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
SE0303135D0 (sv) * 2003-11-25 2003-11-25 Lipocore Holding Ab Controlled food effect composition
EP1906951A4 (en) * 2005-07-01 2009-05-27 Dynogen Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL HYPOMOTILITY AND RELEVANT DISEASES
CN102014907A (zh) * 2008-05-07 2011-04-13 尼克塔治疗公司 外周作用阿片拮抗剂的口服给药
CN101845047B (zh) * 2009-12-31 2011-12-07 南京臣功制药有限公司 一种溴甲基纳曲酮的制备方法
TWI605814B (zh) * 2010-03-11 2017-11-21 惠氏有限責任公司 甲基拿淬松（ｍｅｔｈｙｌｎａｌｔｒｅｘｏｎｅ）之口服製劑及親脂性鹽

Also Published As

Publication number Publication date
IL233266A0 (en) 2014-08-31
CA2859203A1 (en) 2013-06-27
US20190231771A1 (en) 2019-08-01
AU2012359013A1 (en) 2014-06-26
WO2013096444A1 (en) 2013-06-27
CA2859203C (en) 2020-08-25
JP2019048820A (ja) 2019-03-28
EP2793888A4 (en) 2015-10-28
JP2015501849A (ja) 2015-01-19
US20130317050A1 (en) 2013-11-28
MX2014007312A (es) 2014-08-27
CN110384701A (zh) 2019-10-29
EP2793888A1 (en) 2014-10-29
BR112014014805A2 (pt) 2017-06-13
CN104254332A (zh) 2014-12-31
NZ625863A (en) 2016-11-25
AU2017258808A1 (en) 2017-11-23
AU2019203694A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
AU2009201019B2 (en) Dosage form containing oxycodone and naloxone
KR101618929B1 (ko) 파킨슨병의 치료에 있어서 오피오이드 효능제와 오피오이드 길항제의 조합물
US20190231771A1 (en) Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
KR20110133602A (ko) 옥시코돈 및 날록손을 포함하는 즉시 방출 제약 조성물
HUE033133T2 (en) Oral formulations and lipophilic salts of methylnaltrexone
KR20180008918A (ko) 과민성 방광 치료를 위한 베타-3 아드레날린 수용체 작용제 및 무스카린 수용체 길항제의 약학적 배합제
KR20110026013A (ko) 요폐의 치료를 위한 아편유사제 길항제의 용도
US20180098985A1 (en) Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment
KR101971412B1 (ko) 정맥 내 투여용 이부프로펜의 투여
CA2464261A1 (en) Apomorphine-containing dosage form for ameliorating male erectile dysfunction
WO2016004056A1 (en) Pharmaceutical combinations
KR20250145673A (ko) 통증 완화에 유용한 요법 및 조성물
WO2015191686A1 (en) Methods of administering methylnaltrexone
CA2847781C (en) Reducing drug liking in a subject
NZ625863B2 (en) Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
WO2026035694A1 (en) Cebranopadol useful for preventing or reducing opioid induced respiratory depression
EP3328386A1 (en) A prolonged release dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof in the treatment of bladder pain syndrome (bps)
HK1168000A (en) Administration of intravenous ibuprofen

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140718

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171215

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181002

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190826

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20181002

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I